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COMMENTARY
Outcome assessment in
dermatology: a tree in need of
pruning
Clinical Trials in medicine is a multi-billion dollar industry, but
exposes patients to risks and uncertainty, and provide an ever-
increasing amount of information to clinicians. The costs per
individual trial, number of different diseases studied, the num-
ber of participating international centres and patients, and com-
plexity of study designs are increasing. The outcome of the
studies has evolved as well and is now including more detailed
clinical outcomes, patient-reported outcomes (e.g. effect on
specific symptoms, health-related quality of life and treatment
satisfaction), drug tolerability and safety, and costs. To summa-
rize and compare the findings of clinical studies in (network)
meta-analysis, it is important that the study designs are at least
comparable and ideally identical. However, as expected in situa-
tions of exponential growth, we lost oversight of the different
outcomes and their definitions used in the clinical studies in der-
matology. We have neglected the trees in the orchard while pick-
ing low-hanging fruit.
In this issue of the JEADV, Lange et al confirmed the prolifer-
ation of dermatology outcomes.1 They filleted the outcomes in
Figure 1 A tree in need of pruning.
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220 clinical studies of 10 randomly selected, relatively old
(<2015), Cochrane reviews ranging from psoriasis, pemphigus
vulgaris and common warts. They categorized the outcomes in
four areas by a generally accepted filter. Of the four core area’s
investigated, the dermatology trials performed best in the ‘life
impact’ and pathophysiological manifestations (clinical out-
come) and much less on ‘economical’ impact and ‘death’. Not
surprising, they demonstrated a wide variety of 1086 outcomes
of which almost halve were ill defined. Often important infor-
mation was missing concerning measurement tool, time of mea-
surement, unit and delta of the outcomes that was analysed. In
conclusion, they make an urgent call for dermatology-specific
outcome taxonomy to ease the life of reviewers and scientist to
be able to compare the data.
This paper is not an easy read, it is conceptual science. Con-
sidering the metaphor with a tree as is provoked by using the
term taxonomy (i.e. ‘the process of naming and classifying
things such as plants into groups within a larger system,
according to their similarities and differences’) in the title, the
tree is dense (too many separate outcomes), has sick, broken
and dead branches [poor (defined) outcomes], and suffers
under its own weight (too many outcomes). The wild prolifer-
ation of fine branches which reflect the currently used out-
comes, need to be pruned to a couple of thick branches (i.e.
the so called core areas) that are directly linked to the tree
trunk (outcomes in dermatology). The work of the Core Out-
come Set groups demonstrates the benefits of fruitful thick
branches. The HOME initiative (Core Outcome Set group for
atopic eczema), e.g. has develop consensus on WHAT and
HOW to measure pivotal outcomes in eczema2 as is reflected
in a recent network meta-analysis.3 However, further pruning
is clearly needed. The work by Lange at al provides the first
snap shot of this dermatological tree and a strategy on how to
best prepare it for the coming years so it can continue to bare
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